- monoclonal antibody,
- cell membrane,
- growth factors
In various clinical settings such a peripheral vascular disease and diabetes, patients can develop leaky blood vessels that leads to the extravasation of fluid in surrounding tissues, mainly in the lower limbs, ultimately resulting in edema and compromised blood flow. In an attempt to maintain vascular integrity and stability researchers have tried to modulate two key receptors on endothelial cells, Vascular Endothelial Growth Factor Receptor-2 (VEGFR2) and tunica internal endothelial cell kinase 2 (Tie2) receptor using various approaches, including ligand administration and small molecule inhibition of kinase activity on the intracellular part of Tie-2. Various strategies for a therapy include monoclonal antibodies (Mabs) that influence the aforementioned pathways. The current poster describes a monoclonal antibody that binds a cell surface target protein and indirectly modulates the Tie-2 receptor activity.
Available at: http://works.bepress.com/rocco_rotello/25/